Updates in Immunotherapy for Pancreatic Cancer DOI Open Access
Robert C. Chick, Timothy M. Pawlik

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(21), P. 6419 - 6419

Published: Oct. 26, 2024

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options. Due to a variety of cancer cell-intrinsic factors, including KRAS mutations, chemokine production, and other mechanisms that elicit dysregulated host immune response, PDAC often characterized by poor infiltration immune-privileged fibrotic stroma. As understanding the tumor microenvironment (TME) evolves, novel therapies are being developed target immunosuppressive mechanisms. Immune checkpoint inhibitors have efficacy when used alone or radiation. Combinations therapies, along chemotherapy chemoradiation, demonstrated promise in preclinical early clinical trials. Despite dismal response rates for immunotherapy metastatic PDAC, neoadjuvant somewhat encouraging, suggesting incorporation treatment should be earlier disease course. Precision therapy may informed advances transcriptomic sequencing can identify immunophenotypes, allowing more appropriate selection each individual patient. Personalized antigen-specific increasing topic interest, adjuvant using personalized mRNA vaccines prevent recurrence. Further development will need balance precision generalizability cost.

Language: Английский

Characterization of the Pancreatic Neuroendocrine Neoplasm Immune Microenvironment DOI Creative Commons
Filipe Reis Neves,

Ana Luís Martins,

Rui Caetano Oliveira

et al.

Cancer Medicine, Journal Year: 2025, Volume and Issue: 14(7)

Published: March 27, 2025

A tumor is composed of more than tumoral cells. In recent years, there has been an increase in interest and knowledge the microenvironment (TME). The TME integral part tumor, several cells: immune, stromal, endothelial, among others, thus offering a wide range interactions multiple possibilities for targeted therapies environment modulation. While pancreatic ductal adenocarcinoma widely studied, it not very true neuroendocrine neoplasms (PNENs). incidence PNENs increasing and, therefore, important to comprehend their biology evolution efficient since many develop metastasis, including G1 PNENs. This paper focuses on review role

Language: Английский

Citations

0
The mechanism of action and therapeutic potential of tumor-associated macrophages in tumor immune evasion DOI Creative Commons
Kehua Wang, Xu Zhang,

Aiqin Li

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 22, 2025

Tumor-associated macrophages (TAMs) play a multifaceted role in tumor progression. As specialized immune cells, are capable of phagocytosis and digesting foreign substances, as well removing harmful substances including cellular debris cells. Under specific pathological conditions, circulating monocytes can be recruited into the microenvironment differentiate TAMs. Macrophages generally polarized two distinct subpopulations: classically activated (M1) alternatively (M2). TAMs constitute significant proportion mononuclear leukocyte population solid tumors, exhibiting complex dualistic relationship with Substantial evidence indicates that interact facilitating their evasion while promoting invasion metastasis. This review focuses on mechanism regulation response to various macrophage-based tumor-targeted therapeutic strategies. It will provide reference for research macrophage-centered therapy strategies application clinical practice.

Language: Английский

Citations

0
CSF1-CAR Specifically Targets CSF1R+ Pancreatic Cancer Cells and Tumor-Associated Macrophages DOI
Yongjie Zhu,

Ruipu Sun,

Jiawei Fan

et al.

Journal of Immunotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: May 16, 2025

Summary: A highly suppressive tumor immune microenvironment and nonspecific target endow malignant tumors with CAR-T cells. CSF1R is expressed on pancreatic cancer tissues compares normal in GEPIA database M2 macrophages mainly contributing to the (TME), suggesting that a suitable antigen. CSF1 natural ligand of CSF1R, so we constructed CSF1-CAR tested its cytotoxic effect cells vitro. Our results demonstrated CSF1-CAR-T can lyse dependent expression. Meanwhile, also + macrophages, play role eliminating remodeling TME.

Language: Английский

Citations

0
Updates in Immunotherapy for Pancreatic Cancer DOI Open Access
Robert C. Chick, Timothy M. Pawlik

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(21), P. 6419 - 6419

Published: Oct. 26, 2024

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options. Due to a variety of cancer cell-intrinsic factors, including KRAS mutations, chemokine production, and other mechanisms that elicit dysregulated host immune response, PDAC often characterized by poor infiltration immune-privileged fibrotic stroma. As understanding the tumor microenvironment (TME) evolves, novel therapies are being developed target immunosuppressive mechanisms. Immune checkpoint inhibitors have efficacy when used alone or radiation. Combinations therapies, along chemotherapy chemoradiation, demonstrated promise in preclinical early clinical trials. Despite dismal response rates for immunotherapy metastatic PDAC, neoadjuvant somewhat encouraging, suggesting incorporation treatment should be earlier disease course. Precision therapy may informed advances transcriptomic sequencing can identify immunophenotypes, allowing more appropriate selection each individual patient. Personalized antigen-specific increasing topic interest, adjuvant using personalized mRNA vaccines prevent recurrence. Further development will need balance precision generalizability cost.

Language: Английский

Citations

2